Literature DB >> 29607531

Vancomycin-induced acute kidney injury in elderly Chinese patients: a single-centre cross-sectional study.

Kun-Ming Pan1, Yi Wu1, Can Chen1, Zhang-Zhang Chen1, Jian-An Xu1, Lei Cao1, Qing Xu1, Wei Wu1, Pei-Fang Dai1, Xiao-Yu Li1, Qian-Zhou Lv1.   

Abstract

AIMS: The objective of the present study was to investigate the current situation concerning, and risk factors for, vancomycin (VAN)-induced acute kidney injury (VI-AKI) in elderly Chinese patients, to assess outcomes and risk factors in patients who have developed VI-AKI, in order to provide suggestions for improving the prevention and treatment of this condition in these patients.
METHOD: We retrospectively identified elderly older inpatients who had received four or more doses of VAN treatment. We compared patients with VI-AKI with those who received VAN treatment and had not developed AKI (NO-AKI). We defined VI-AKI as developing AKI during VAN therapy or within 3 days after withdrawal of VAN.
RESULTS: A total of 647 out of 862 elderly inpatients were included in the study. Among those excluded, in 89.3% of cases (192/215) this was because of lack of data on serum creatinine (SCr). Among included patients, 32.5% (210/647) of patients received therapeutic drug monitoring (TDM) during VAN therapy. In 66.9% of cases (424/634), there was insufficient TDM, and in 3.9% (25/634) this was appropriate. A total of 102 patients had confirmed VI-AKI, with an incidence of 15.8% (102/647). Multiple logistic regression analysis revealed that hyperuricaemia [odds ratio (OR) = 3.045; P = 0.000)], mechanical ventilation (OR = 1.906; P = 0.022) and concomitant vasopressor therapy (OR = 1.919; P = 0.027) were independent risk factors for VI-AKI; higher serum albumin (OR = 0.885; P = 0.000) was determined to be an independent protective factor for VI-AKI.
CONCLUSIONS: For the elderly Chinese patients treated with VAN, there was insufficient monitoring of SCr, too little use of VAN TDM, and lower rate of patients whose VAN though serum concentrations were not obtained at the correct time. We recommend that hospital managers increase investment in clinical pharmacists, to strengthen professional management. Patients with concomitant hyperuricaemia and on mechanical ventilation and vasopressor therapy should be paid more attention, and a higher serum albumin was determined to be an independent protective factor for VI-AKI.
© 2018 The British Pharmacological Society.

Entities:  

Keywords:  acute kidney injury; older patients; risk factors; vancomycin

Mesh:

Substances:

Year:  2018        PMID: 29607531      PMCID: PMC6046479          DOI: 10.1111/bcp.13594

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  35 in total

1.  Lowering serum uric acid to prevent acute kidney injury.

Authors:  A Ahsan Ejaz; Bhagwan Dass; Ganesh Kambhampati; Noel I Ejaz; Natallia Maroz; Gurjit S Dhatt; Amir A Arif; Chirag Faldu; Miguel A Lanaspa; Gaurav Shah; Richard J Johnson
Journal:  Med Hypotheses       Date:  2012-04-12       Impact factor: 1.538

2.  Impact of a Pharmacist-Initiated Vancomycin Monitoring Program.

Authors:  Andrew P Smith; Catherine A Millares-Sipin; Marian James; Henry Cohen
Journal:  Consult Pharm       Date:  2016-09

3.  Risk factors for vancomycin nephrotoxicity: still a matter of debate*.

Authors:  Verônica T Costa e Silva; Lia J Marçal; Emmanuel A Burdmann
Journal:  Crit Care Med       Date:  2014-12       Impact factor: 7.598

Review 4.  Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter.

Authors:  S J van Hal; D L Paterson; T P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2012-11-19       Impact factor: 5.191

5.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-02-01       Impact factor: 9.079

6.  Vancomycin-associated acute kidney injury in pediatric cardiac intensive care patients.

Authors:  Brady S Moffett; Pamela S Hilvers; Kimberly Dinh; Ayse A Arikan; Paul Checchia; Ronald Bronicki
Journal:  Congenit Heart Dis       Date:  2014-06-17       Impact factor: 2.007

7.  Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care.

Authors:  Puttarin Kulchaitanaroaj; John M Brooks; Nathorn Chaiyakunapruk; Amber M Goedken; Elizabeth A Chrischilles; Barry L Carter
Journal:  J Hypertens       Date:  2017-01       Impact factor: 4.844

8.  Vancomycin-induced acute kidney injury in elderly Chinese patients: a single-centre cross-sectional study.

Authors:  Kun-Ming Pan; Yi Wu; Can Chen; Zhang-Zhang Chen; Jian-An Xu; Lei Cao; Qing Xu; Wei Wu; Pei-Fang Dai; Xiao-Yu Li; Qian-Zhou Lv
Journal:  Br J Clin Pharmacol       Date:  2018-05-24       Impact factor: 4.335

Review 9.  Could uric acid have a role in acute renal failure?

Authors:  A Ahsan Ejaz; Wei Mu; Duk-Hee Kang; Carlos Roncal; Yuri Y Sautin; George Henderson; Isabelle Tabah-Fisch; Birgit Keller; Thomas M Beaver; Takahiko Nakagawa; Richard J Johnson
Journal:  Clin J Am Soc Nephrol       Date:  2006-12-06       Impact factor: 8.237

10.  Vancomycin-associated acute kidney injury: A cross-sectional study from a single center in China.

Authors:  Kunming Pan; Lingyun Ma; Qian Xiang; Xueying Li; Haixia Li; Ying Zhou; Li Yang; Yimin Cui
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

View more
  4 in total

1.  Vancomycin-induced acute kidney injury in elderly Chinese patients: a single-centre cross-sectional study.

Authors:  Kun-Ming Pan; Yi Wu; Can Chen; Zhang-Zhang Chen; Jian-An Xu; Lei Cao; Qing Xu; Wei Wu; Pei-Fang Dai; Xiao-Yu Li; Qian-Zhou Lv
Journal:  Br J Clin Pharmacol       Date:  2018-05-24       Impact factor: 4.335

2.  Predictive performance of reported vancomycin population pharmacokinetic model in patients with different renal function status, especially those with augmented renal clearance.

Authors:  Yan-Xia Yu; Jian Lu; Hao-di Lu; Lan Li; Jing-Jing Li; Lu Shi; Lu-Fen Duan; Zhi-Wei Zhuang; Su-Dong Xue; Yi Shen; Lian Tang
Journal:  Eur J Hosp Pharm       Date:  2021-01-07

3.  Effect of First Trough Vancomycin Concentration on the Occurrence of AKI in Critically Ill Patients: A Retrospective Study of the MIMIC-IV Database.

Authors:  Longzhu Li; Luming Zhang; Shaojin Li; Fengshuo Xu; Li Li; Shuna Li; Jun Lyu; Haiyan Yin
Journal:  Front Med (Lausanne)       Date:  2022-04-14

4.  Development and Validation of a Risk Prediction Model of Vancomycin-Associated Nephrotoxicity in Elderly Patients: A Pilot Study.

Authors:  Chen Pan; Aiping Wen; Xingang Li; Dandan Li; Yang Zhang; Yin Liao; Yue Ren; Su Shen
Journal:  Clin Transl Sci       Date:  2020-01-09       Impact factor: 4.689

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.